# Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment

> **NCT02174276** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 195 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Tenofovir disoproxil fumarate
- **BIOLOGICAL:** GS-4774

## Key facts

- **NCT ID:** NCT02174276
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-24
- **Primary completion:** 2016-02-17
- **Final completion:** 2018-05-30
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174276, "Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02174276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*